Switch theme
Sign up to access all valuation multiples
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
2012
480
LTM Revenue $30.7M
LTM EBITDA -$169M
$194M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
uniQure has a last 12-month revenue of $30.7M and a last 12-month EBITDA of -$169M.
In the most recent fiscal year, uniQure achieved revenue of $27.1M and an EBITDA of -$161M.
uniQure expects next 12-month revenue of XXX and NTM EBITDA of XXX
See uniQure valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $15.8M | $27.1M | XXX | XXX | XXX |
| Gross Profit | $103M | $2.2M | XXX | XXX | XXX |
| Gross Margin | 651% | 8% | XXX | XXX | XXX |
| EBITDA | -$253M | -$161M | XXX | XXX | XXX |
| EBITDA Margin | -1598% | -593% | XXX | XXX | XXX |
| Net Profit | -$127M | -$308M | XXX | XXX | XXX |
| Net Margin | -800% | -1137% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, uniQure's stock price is $9.
uniQure has current market cap of $496M, and EV of $194M.
See uniQure trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $194M | $496M | XXX | XXX | XXX | XXX | $-4.63 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, uniQure has market cap of $496M and EV of $194M.
uniQure's trades at 6.3x LTM EV/Revenue multiple, and -1.2x LTM EBITDA.
Analysts estimate uniQure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for uniQure and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $194M | XXX | XXX | XXX |
| EV/Revenue | 7.2x | XXX | XXX | XXX |
| EV/EBITDA | -1.2x | XXX | XXX | XXX |
| P/E | -2.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpuniQure's NTM/LTM revenue growth is 88%
uniQure's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, uniQure's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate uniQure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for uniQure and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 71% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -593% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -36% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -505% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 187% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 530% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 700% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
uniQure acquired XXX companies to date.
Last acquisition by uniQure was XXXXXXXX, XXXXX XXXXX XXXXXX . uniQure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was uniQure founded? | uniQure was founded in 2012. |
| Where is uniQure headquartered? | uniQure is headquartered in United States of America. |
| How many employees does uniQure have? | As of today, uniQure has 480 employees. |
| Who is the CEO of uniQure? | uniQure's CEO is Mr. Matthew C. Kapusta. |
| Is uniQure publicy listed? | Yes, uniQure is a public company listed on NAS. |
| What is the stock symbol of uniQure? | uniQure trades under QURE ticker. |
| When did uniQure go public? | uniQure went public in 2014. |
| Who are competitors of uniQure? | Similar companies to uniQure include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of uniQure? | uniQure's current market cap is $496M |
| What is the current revenue of uniQure? | uniQure's last 12-month revenue is $30.7M. |
| What is the current EBITDA of uniQure? | uniQure's last 12-month EBITDA is -$169M. |
| What is the current EV/Revenue multiple of uniQure? | Current revenue multiple of uniQure is 6.3x. |
| What is the current EV/EBITDA multiple of uniQure? | Current EBITDA multiple of uniQure is -1.2x. |
| What is the current revenue growth of uniQure? | uniQure revenue growth between 2023 and 2024 was 71%. |
| Is uniQure profitable? | Yes, uniQure is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
